Recent News

• 02.11.2026 - Bio-Techne Announces Changes to its Leadership Team
• 02.04.2026 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 02.04.2026 - Bio-Techne Releases Second Quarter Fiscal 2026 Results
• 02.04.2026 - Bio-Techne Declares Dividend
• 02.02.2026 - Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
• 01.28.2026 - Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers
• 01.20.2026 - Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
• 12.23.2025 - Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference
• 12.11.2025 - Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology
• 12.09.2025 - Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis

Recent Filings

• 02.11.2026 - 8-K Current report
• 02.11.2026 - EX-99.1 EX-99.1
• 02.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 8-K Current report
• 02.04.2026 - EX-99.1 EX-99.1
• 02.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors